Analysts Set Capricor Therapeutics, Inc. (NASDAQ:CAPR) Price Target at $50.30

Capricor Therapeutics, Inc. (NASDAQ:CAPR) has been assigned a consensus rating of “Moderate Buy” from the ten research firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $53.6667.

CAPR has been the subject of several research analyst reports. Cantor Fitzgerald set a $62.00 price target on shares of Capricor Therapeutics and gave the stock an “overweight” rating in a research report on Friday, March 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Monday, June 15th. Piper Sandler restated an “overweight” rating and issued a $58.00 price objective (up from $45.00) on shares of Capricor Therapeutics in a report on Friday, March 13th. LADENBURG THALM/SH SH raised Capricor Therapeutics to a “strong-buy” rating in a research note on Thursday, June 25th. Finally, B. Riley Financial raised their target price on Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a report on Friday, March 13th.

Insider Activity at Capricor Therapeutics

In other news, CFO Anthony Bergmann sold 25,000 shares of the company’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $31.70, for a total value of $792,500.00. Following the completion of the transaction, the chief financial officer directly owned 8,223 shares in the company, valued at approximately $260,669.10. This represents a 75.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 50,000 shares of company stock worth $1,551,658 over the last 90 days. Insiders own 9.20% of the company’s stock.

Institutional Trading of Capricor Therapeutics

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in shares of Capricor Therapeutics by 16.1% in the 4th quarter. Vanguard Group Inc. now owns 2,561,880 shares of the biotechnology company’s stock valued at $73,936,000 after acquiring an additional 355,161 shares during the last quarter. Suvretta Capital Management LLC bought a new position in Capricor Therapeutics during the fourth quarter worth $51,533,000. Tang Capital Management LLC acquired a new position in Capricor Therapeutics in the fourth quarter worth $49,062,000. RA Capital Management L.P. acquired a new position in Capricor Therapeutics in the fourth quarter worth $43,516,000. Finally, Geode Capital Management LLC increased its stake in Capricor Therapeutics by 5.8% during the fourth quarter. Geode Capital Management LLC now owns 1,017,332 shares of the biotechnology company’s stock valued at $29,367,000 after purchasing an additional 55,766 shares during the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Stock Performance

Capricor Therapeutics stock opened at $23.21 on Monday. The stock has a market cap of $1.34 billion, a PE ratio of -10.00 and a beta of 0.42. The stock has a 50-day moving average price of $28.87 and a 200 day moving average price of $28.27. Capricor Therapeutics has a 52 week low of $4.30 and a 52 week high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.04). On average, equities analysts predict that Capricor Therapeutics will post -0.49 EPS for the current year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.